Table 1 Clinicopathological characteristics of the breast cancer patient cohort
From: Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer
Parameter | Randomized untreated (n=232) | Tamoxifen (n=212) | Total (n=444) |
|---|---|---|---|
Age at diagnosis (year) | |||
Median | 45.00 | 45.00 | 45.00 |
Range | 26–57 | 25–57 | 25–57 |
Follow-up time without death from breast cancer | |||
Median | 28.09 | 28.56 | 28.41 |
10th percentile | 20.48 | 21.35 | 20.56 |
90th percentile | 30.85 | 30.72 | 30.74 |
Tumor size (mm) | |||
Median | 23.00 | 25.00 | 24.00 |
Range | 2–50 | 8–75 | 2–75 |
Tumor histology | |||
Ductal | 194 | 176 | 370 |
Lobular | 18 | 17 | 35 |
Medullar | 13 | 9 | 22 |
Missing: 17 | |||
Tumor grade | |||
Grade 1 | 31 | 23 | 54 |
Grade 2 | 100 | 86 | 186 |
Grade 3 | 96 | 92 | 188 |
Missing: 16 | |||
Lymph node (LN) status | |||
LN Positive | 166 | 144 | 310 |
LN Negative | 65 | 67 | 132 |
Missing: 2 | |||
Estrogen receptor (ERα) | |||
ERα positive | 173 | 144 | 317 |
ERα negative | 47 | 49 | 96 |
Missing: 31 | |||
Progesterone receptor (PR) | |||
PR positive | 122 | 108 | 230 |
PR negative | 63 | 61 | 124 |
Missing: 90 | |||
Human epidermal growth factor receptor 2 (HER2) | |||
HER2 negative | 186 | 172 | 358 |
HER2 positive | 35 | 25 | 60 |
Missing: 26 | |||
Progranulin expression | |||
High | 66 | 73 | 139 |
Low | 149 | 124 | 273 |
Missing: 32 | |||
Sortilin expression | |||
High | 116 | 109 | 225 |
Low | 107 | 95 | 202 |
Missing: 17 | |||